Pharmaceutical company MSD announced on Wednesday (October 6) that it has signed an agreement with Singapore to supply molnupiravir, a research antiviral drug for the treatment of COVID-19, after it has been authorized or approved.
The drug, which is being developed in collaboration with Ridgeback Biotherapy, is currently being evaluated in two Phase 3 clinical trials, the company said in a press release.
The company said last Friday that trials showed that molnupiravir reduced the risk of hospitalization or death in patients with mild to moderate COVID-19 by about 50%.
It has also been shown to be effective against the most common variants of the COVID-19 virus, such as the highly contagious delta mutant.
Under the agreement, Singapore will be able to access the drug once “certain regulatory milestones are achieved”, said MSD.
CNA has contacted the Ministry of Health and Health Sciences Authority for more information.
“MSD believes a range of medicines and vaccines will be needed to make an impact on the pandemic,” said Ms Pang Lai Li, managing director for MSD in Singapore and Malaysia.
“This agreement is another example of Singapore’s forward-looking strategy of pandemic management and the Government’s commitment to investing in innovative medicines and vaccines to combat the pandemic.”